Loading...
Tamoxifen, a selective estrogen receptor modulator (SERM), is FDA-approved to prevent breast cancer in high-risk women. Few U.S. women use it for prevention, though, partly due to the elevated risk for endometrial cancer and thromboembolic disease. To compare the safety and efficacy between a newer SERM, raloxifene (60 mg daily), and tamoxifen (20 mg daily), investigators from this government- and manufacturer-supported trial randomized almost 20,000 postmenopausal women (mean age, 58.5; 93.5% white) with elevated breast-cancer risk to receive either treatment for 5 years.
The incidence of invasive breast cancer was almost identical in the tamoxifen and raloxifene groups (4.3 and 4.4 per 1000 person-years, respectively). Also similar between…